Breast cancer survival in Nordic BRCA2 mutation carriers—unconventional association with oestrogen receptor status
Gespeichert in:
| Titel: | Breast cancer survival in Nordic BRCA2 mutation carriers—unconventional association with oestrogen receptor status |
|---|---|
| Autoren: | Elinborg J. Olafsdottir, Ake Borg, Maj-Britt Jensen, Anne-Marie Gerdes, Anna L. V. Johansson, Rosa B. Barkardottir, Oskar T. Johannsson, Bent Ejlertsen, Ida Marie Heeholm Sønderstrup, Eivind Hovig, Anne-Vibeke Lænkholm, Thomas van Overeem Hansen, Gudridur H. Olafsdottir, Maria Rossing, Jon G. Jonasson, Stefan Sigurdsson, Niklas Loman, Martin P. Nilsson, Steven A. Narod, Laufey Tryggvadottir |
| Quelle: | Br J Cancer Olafsdottir, E J, Borg, A, Jensen, M-B, Gerdes, A-M, Johansson, A L V, Barkardottir, R B, Johannsson, O T, Ejlertsen, B, Sønderstrup, I M H, Hovig, E, Lænkholm, A-V, Hansen, T V O, Olafsdottir, G H, Rossing, M, Jonasson, J G, Sigurdsson, S, Loman, N, Nilsson, M P, Narod, S A & Tryggvadottir, L 2020, ' Breast cancer survival in Nordic BRCA2 mutation carriers-unconventional association with oestrogen receptor status ', British Journal of Cancer, vol. 123, no. 11, pp. 1608-1615 . https://doi.org/10.1038/s41416-020-01056-4 |
| Verlagsinformationen: | Springer Science and Business Media LLC, 2020. |
| Publikationsjahr: | 2020 |
| Schlagwörter: | Adult, Aged, 80 and over, BRCA2 Protein, Heterozygote, Breast Neoplasms, Breast Neoplasms/genetics, Middle Aged, Scandinavian and Nordic Countries, BRCA2 Protein/genetics, Article, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, Receptors, Estrogen, Receptors, Mutation, 80 and over, Humans, Female, Genetic Predisposition to Disease, Estrogen/metabolism, Receptors, Estrogen/metabolism, Aged |
| Beschreibung: | Background The natural history of breast cancer among BRCA2 carriers has not been clearly established. In a previous study from Iceland, positive ER status was a negative prognostic factor. We sought to identify factors that predicted survival after invasive breast cancer in an expanded cohort of BRCA2 carriers. Methods We studied 608 women with invasive breast cancer and a pathogenic BRCA2 mutation (variant) from four Nordic countries. Information on prognostic factors and treatment was retrieved from health records and by analysis of archived tissue specimens. Hazard ratios (HR) were estimated for breast cancer-specific survival using Cox regression. Results About 77% of cancers were ER-positive, with the highest proportion (83%) in patients under 40 years. ER-positive breast cancers were more likely to be node-positive (59%) than ER-negative cancers (34%) (P P = 0.03); thereafter, the effect was adverse (HR = 1.91; 95% CI 1.07–3.39, P = 0.03). The adverse effect of positive ER status was limited to women who did not undergo endocrine treatment (HR = 2.36; 95% CI 1.26–4.44, P = 0.01) and patients with intact ovaries (HR = 1.99; 95% CI 1.11–3.59, P = 0.02). Conclusions The adverse effect of a positive ER status in BRCA2 carriers with breast cancer may be contingent on exposure to ovarian hormones. |
| Publikationsart: | Article Other literature type |
| Dateibeschreibung: | application/pdf |
| Sprache: | English |
| ISSN: | 1532-1827 0007-0920 |
| DOI: | 10.1038/s41416-020-01056-4 |
| Zugangs-URL: | https://www.nature.com/articles/s41416-020-01056-4.pdf https://pubmed.ncbi.nlm.nih.gov/32939053 https://www.ncbi.nlm.nih.gov/pubmed/32939053 https://portal.research.lu.se/en/publications/breast-cancer-survival-in-nordic-brca2-mutation-carriersunconvent https://www.nature.com/articles/s41416-020-01056-4 https://europepmc.org/article/PMC/PMC7686356 https://pubmed.ncbi.nlm.nih.gov/32939053/ https://lup.lub.lu.se/search/publication/0b4cc50f-f6df-4cff-a226-c48768744d93 https://curis.ku.dk/ws/files/288874261/Breast_cancer_survival_in_Nordic_BRCA2_mutation_carriers_unconventional_association_with_oestrogen_receptor_status_publisher_version_ccby_.pdf |
| Rights: | CC BY URL: http://creativecommons.org/licenses/by/4.0/Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0). |
| Dokumentencode: | edsair.doi.dedup.....e7e7ec289186b38b15f088b6d5d816bd |
| Datenbank: | OpenAIRE |
Full Text 
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstract: | Background The natural history of breast cancer among BRCA2 carriers has not been clearly established. In a previous study from Iceland, positive ER status was a negative prognostic factor. We sought to identify factors that predicted survival after invasive breast cancer in an expanded cohort of BRCA2 carriers. Methods We studied 608 women with invasive breast cancer and a pathogenic BRCA2 mutation (variant) from four Nordic countries. Information on prognostic factors and treatment was retrieved from health records and by analysis of archived tissue specimens. Hazard ratios (HR) were estimated for breast cancer-specific survival using Cox regression. Results About 77% of cancers were ER-positive, with the highest proportion (83%) in patients under 40 years. ER-positive breast cancers were more likely to be node-positive (59%) than ER-negative cancers (34%) (P P = 0.03); thereafter, the effect was adverse (HR = 1.91; 95% CI 1.07–3.39, P = 0.03). The adverse effect of positive ER status was limited to women who did not undergo endocrine treatment (HR = 2.36; 95% CI 1.26–4.44, P = 0.01) and patients with intact ovaries (HR = 1.99; 95% CI 1.11–3.59, P = 0.02). Conclusions The adverse effect of a positive ER status in BRCA2 carriers with breast cancer may be contingent on exposure to ovarian hormones. |
|---|---|
| ISSN: | 15321827 00070920 |
| DOI: | 10.1038/s41416-020-01056-4 |